THE VERY NEXT DAY THE MARKET TOOK OFF!!! LOL AND NEVER TURNED BACK... THIS IS THE VERY WORST CALL!!!
GBA Presents: RADIO SAVANT-!
- Thread starter stonedinvestor
- Start date
THE VERY NEXT DAY THE MARKET TOOK OFF!!! LOL AND NEVER TURNED BACK... THIS IS THE VERY WORST CALL!!!
I was wondering why our AVAV went up so much...
AVAV AeroVironment, Inc.
$115.051 +9.76(+20.74%)4:00 PM 09/06/23
NASDAQ |$USD |Post-Market:$116.00+0.95(+0.83%)7:56 PM
Same Line of work... KTOS...... Tic, Tic, Tic...
For Immediate Release:
GBA SELL-! LEU REMOVED**************
GBA Turns $33,000 Into $52,000+
Centrus Energy Corp. (LEU)
NYSE American - Nasdaq Real Time Price.
52.78+0.64(+1.24%)<---- we OUT!
What a way to start a weekend! Bud lights on me!!!
One stock I am really surprised we are not up more is
Transocean Ltd. - they have a backlog of $9.4 BILLION<-----
and we are up a buck. just don't get it.
Transocean Ltd. - they have a backlog of $9.4 BILLION<-----
and we are up a buck. just don't get it.
For Immediate Release:
GBA SELL-! LEU REMOVED**************
GBA Turns $33,000 Into $52,000+
Centrus Energy Corp. (LEU)
NYSE American - Nasdaq Real Time Price.
52.78+0.64(+1.24%)<---- we OUT!
What a way to start a weekend! Bud lights on me!!!
Got a few questions about Centrus. Yes it did go up after we sold. Quite abit more I think it hit $60.
This is one of my best calls of the year. I am not at this point tempted to get back in.
Now back @$53
Tesla trajectory weakening, Roth MKM says
Tesla valuation 'looks increasingly unsustainable' post Q3 report, says JPMorganGeneral Motors »
Spectral AI's DeepView SnapShot system UKCA mark, FDA class 1 classification » 08:05 MDAI
Bitdeer board approves $2M share repurchase program » 08:04 BTDR
Stepan upgraded to Buy from Neutral at CL King » 07:43 SCL
Las Vegas Sands price target raised to $68 from $66 at Macquarie » 07:38 LVS
Green Thumb's incredibles launches Fast-Acting Pineapple Express Gummies » 07:11 GTBIF
Nu Holdings price target raised to $16, named a Top Pick at Morgan Stanley » 07:01 NU
Tesla valuation 'looks increasingly unsustainable' post Q3 report, says JPMorganGeneral Motors »
Spectral AI's DeepView SnapShot system UKCA mark, FDA class 1 classification » 08:05 MDAI
Bitdeer board approves $2M share repurchase program » 08:04 BTDR
Stepan upgraded to Buy from Neutral at CL King » 07:43 SCL
Las Vegas Sands price target raised to $68 from $66 at Macquarie » 07:38 LVS
Green Thumb's incredibles launches Fast-Acting Pineapple Express Gummies » 07:11 GTBIF
Nu Holdings price target raised to $16, named a Top Pick at Morgan Stanley » 07:01 NU
Why?
Amylyx price target lowered to $46 from $48 at Mizuho » 06:39 AMLX
Mr Mizuho $2, couldn't you of just remained quiet today?
Amylyx price target lowered to $46 from $48 at Mizuho » 06:39 AMLX
Mr Mizuho $2, couldn't you of just remained quiet today?
Oppenheimer bullish on Amazon ahead of quarterly results
UPGRADE OF THE DAY-
Rhythm Pharmaceuticals price target raised to $70 from $52 at Canaccord » 06:30 RYTM
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
Rhythm Pharmaceuticals, Inc.
Tue, October 17, 2023, 4:01 PM EDT
Rhythm Pharmaceuticals, Inc.
-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment --
-- Three of 11 pediatric patients with hypothalamic obesity achieved normal weight at one year based on NIH, WHO weight classifications --
-- Additional long-term study data show clinically relevant weight reductions in patients with Bardet-Biedl syndrome and POMC or LEPR deficiency obesity --
-- Conference call scheduled for October 18, 2023, at 8:00 a.m. ET --
BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced several data presentations showing that setmelanotide therapy resulted in sustained and deepened weight loss in patients with severe obesity caused by rare MC4R pathway diseases during The Obesity Society’s Annual Meeting at ObesityWeek®.
Rhythm and its collaborators delivered a total of six presentations at the conference in Dallas from October 14 to 17. Presentation highlights include the following results from Rhythm’s open-label, long-term extension studies evaluating setmelanotide in individuals with hypothalamic obesity, Bardet-Biedl syndrome (BBS) or obesity due to POMC or LEPR deficiency, as of a data cutoff date of June 13, 2023:
UPGRADE OF THE DAY-
Rhythm Pharmaceuticals price target raised to $70 from $52 at Canaccord » 06:30 RYTM
Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
Rhythm Pharmaceuticals, Inc.
Tue, October 17, 2023, 4:01 PM EDT
Rhythm Pharmaceuticals, Inc.
-- Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment --
-- Three of 11 pediatric patients with hypothalamic obesity achieved normal weight at one year based on NIH, WHO weight classifications --
-- Additional long-term study data show clinically relevant weight reductions in patients with Bardet-Biedl syndrome and POMC or LEPR deficiency obesity --
-- Conference call scheduled for October 18, 2023, at 8:00 a.m. ET --
BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced several data presentations showing that setmelanotide therapy resulted in sustained and deepened weight loss in patients with severe obesity caused by rare MC4R pathway diseases during The Obesity Society’s Annual Meeting at ObesityWeek®.
Rhythm and its collaborators delivered a total of six presentations at the conference in Dallas from October 14 to 17. Presentation highlights include the following results from Rhythm’s open-label, long-term extension studies evaluating setmelanotide in individuals with hypothalamic obesity, Bardet-Biedl syndrome (BBS) or obesity due to POMC or LEPR deficiency, as of a data cutoff date of June 13, 2023:
- 25.5% reduction in mean body mass index (BMI) from baseline in patients with hypothalamic obesity (n=12) at one year;
- 16.0% reduction in mean BMI in adult patients with Bardet-Biedl syndrome (BBS) (n=9) at three years;
- 0.7 reduction in mean BMI Z score in pediatric patients younger than 18 with BBS (n=15) at three years;
- 20.3% reduction in mean BMI in adult patients with obesity due to POMC or LEPR deficiency (n=11) at four years; and
- 1.2 reduction in mean BMI Z score in pediatric patients younger than 18 due to POMC or LEPR deficiency at four years.
OMG I think it was two years ago I said all of this:
Inflation is higher than the Fed wants. The problem could be its target.
https://finance.yahoo.com/news/infl...he-problem-could-be-its-target-185535285.html
Inflation is higher than the Fed wants. The problem could be its target.
https://finance.yahoo.com/news/infl...he-problem-could-be-its-target-185535285.html
GBA BUY AGYS-! $43.40
WATCHING FIGS
<<SAY IT TOGETHER CHILDREN: STONEY IS THE VERY BEST.-!>>
AGYS-> NEW PURCHASE STORMS OUT OF GATE-
Agilysys, Inc. (AGYS)
NasdaqGS - NasdaqGS Real Time Price.
46.80+2.08 (+4.65%)<----------------
As of 02:04PM EDT.
GBA SALE //////// $43-------------------> $79
Agilysys, Inc. (AGYS)
NasdaqGS - NasdaqGS Real Time Price.
79.49+15.59(+24.40%)<-------------------------
You can probably tell by my lack of enthusiasm I let this one go with a measly $10 gain.